Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immix Biopharma (IMMX) Cash from Financing Activities (2021 - 2026)

Quarterly results put Cash from Financing Activities at -$37561.0 for Q1 2026, changed N/A from a year ago — trailing twelve months through Mar 2026 was $106.2 million (changed N/A YoY), and the annual figure for FY2025 was $107.4 million, up 573.33%.

Immix Biopharma has reported Cash from Financing Activities over the past 6 years, most recently at -$37561.0 for Q1 2026.

  • Cash from Financing Activities reached -$37561.0 in Q1 2026 per IMMX's latest filing, down from $95.7 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $95.7 million in Q4 2025 and bottomed at -$105963.0 in Q2 2022.
  • Median Cash from Financing Activities over the past 5 years was $2.9 million (2022), compared with a mean of $12.8 million.
  • The largest annual shift saw Cash from Financing Activities crashed 228.71% in 2022 before it surged 13311.62% in 2024.
  • Over 5 years, Cash from Financing Activities stood at $424276.0 in 2022, then soared by 38.28% to $586692.0 in 2023, then skyrocketed by 2618.39% to $15.9 million in 2024, then skyrocketed by 499.86% to $95.7 million in 2025, then tumbled by 100.04% to -$37561.0 in 2026.
  • Business Quant data shows Cash from Financing Activities for IMMX at -$37561.0 in Q1 2026, $95.7 million in Q4 2025, and $10.6 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 7.00 Mn
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -600,000.00
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - 53,000.00
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn -538.80 Mn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn -802.20 Mn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 15.71 Mn
10 Immix Biopharma 476.17 Mn 476.17 Mn - -37,561.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -37,561.00
Mar 31, 2026 -37,561.00
Dec 31, 2025 95.67 Mn
Dec 31, 2025 95.67 Mn
Sep 30, 2025 10.61 Mn
Sep 30, 2025 10.61 Mn
Mar 31, 2024 15.95 Mn
Mar 31, 2024 15.95 Mn
Dec 31, 2023 586,692.00
Dec 31, 2023 586,692.00
Sep 30, 2023 10.07 Mn
Sep 30, 2023 10.07 Mn
Jun 30, 2023 4.69 Mn
Jun 30, 2023 4.69 Mn
Mar 31, 2023 118,916.00
Mar 31, 2023 118,916.00
Dec 31, 2022 424,276.00
Dec 31, 2022 424,276.00
Jun 30, 2022 -105,963.00
Jun 30, 2022 -105,963.00
Mar 31, 2022 2.91 Mn
Mar 31, 2022 2.91 Mn
Dec 31, 2021 18.72 Mn
Dec 31, 2021 18.72 Mn
Sep 30, 2021 -18,349.00
Sep 30, 2021 -18,349.00
Jun 30, 2021 82,327.00
Jun 30, 2021 82,327.00
Mar 31, 2021 65,000.00
Mar 31, 2021 65,000.00